{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Search results for fezolinetant in Standardized Name (approximate match)
Showing 1 - 1 of 1 results
Status:
US Approved Rx
(2023)
Source:
NDA216578
(2023)
Source URL:
First approved in 2023
Source:
NDA216578
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Fezolinetant (ESN-364) is an antagonist of the neurokinin-3 receptor. It suppresses the hypothalamic-pituitary-gonadal axis. Ogeda is developing fezolinetant for the treatment of hot flashes (vasomotor symptoms) in postmenopausal women.
